Glaukos (NYSE: GKOS) revenue
Glaukos reported revenue of $507.4m for fiscal 2025, 32.3% more than in fiscal 2024 ($383.5m). Since fiscal 2016 its revenue has grown by 343.6%, an average growth of 18.0% a year.
Glaukos has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2020, −5.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $507.4m | +32.3% | −$199.6m | −39.3% |
| 2024 | $383.5m | +21.9% | −$122.4m | −31.9% |
| 2023 | $314.7m | +11.3% | −$128.7m | −40.9% |
| 2022 | $282.9m | −3.8% | −$82.3m | −29.1% |
| 2021 | $294.0m | +30.7% | −$32.9m | −11.2% |
| 2020 | $225.0m | −5.1% | −$123.6m | −54.9% |
| 2019 | $237.0m | +30.7% | −$50.3m | −21.2% |
| 2018 | $181.3m | +13.8% | −$13.0m | −7.2% |
| 2017 | $159.3m | +39.2% | −$2.3m | −1.4% |
| 2016 | $114.4m | — | $4.2m | 3.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Glaukos revenue compared with its sector
By revenue for its latest fiscal year, Glaukos ranks 192nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Glaukos, 32.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 190th | Veracyte | $517.1m | 16.0% |
| 191st | ADMA Biologics | $510.2m | 19.6% |
| 192nd | Glaukos | $507.4m | 32.3% |
| 193rd | STLN | $502.7m | 27.8% |
| 194th | BridgeBio Pharma | $502.1m | 126.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Glaukos
- How much revenue did Glaukos make in fiscal 2025?
- Glaukos reported revenue of $507.4m for fiscal 2025, compared with $383.5m in fiscal 2024.
- How much has the revenue of Glaukos grown?
- Between fiscal 2016 and fiscal 2025 it went from $114.4m to $507.4m: 343.6% more, an average growth of 18.0% a year.
- What was the best year for revenue at Glaukos?
- Of its last 10 fiscal years, fiscal 2025, with $507.4m.
- Where does Glaukos rank in its sector by revenue?
- It ranks 192nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Glaukos come from?
- From the annual report (Form 10-K) that Glaukos files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Glaukos files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Glaukos: the Glaukos page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.